American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced that its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer will be highlighted at the American Foregut Society's (AFS) 2024 Annual Meeting from September 26-28, 2024. Dr. Dan Lister, AFS President-elect, will lead a session titled "Finding Barrett's - Time to Ditch the Scope?" discussing EsoGuard as a non-invasive alternative to screening upper endoscopy.
This follows the AFS's recent open letter advocating for medical policy coverage of EsoGuard by commercial payors, emphasizing its strong scientific evidence and incorporation in AFS physicians' practices. The session will explore EsoGuard's role in triaging at-risk patients and enabling efficient use of endoscopy resources for early detection and prevention of esophageal cancer.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ha annunciato che il suo EsoGuard® Esophageal DNA Test per la rilevazione precoce del precancro esofageo sarà messo in evidenza durante il Meeting Annuale della American Foregut Society (AFS) 2024 che si terrà dal 26 al 28 settembre 2024. Il Dr. Dan Lister, presidente eletto dell'AFS, condurrà una sessione intitolata "Finding Barrett's - È ora di abbandonare la sonda?" discutendo di EsoGuard come un'alternativa non invasiva alla screening endoscopia superiore.
Questo segue una recente lettera aperta dell'AFS che sostiene la copertura della polizza medica per EsoGuard da parte degli assicuratori commerciali, enfatizzando la sua forte evidenza scientifica e l'integrazione nella pratica dei medici AFS. La sessione esplorerà il ruolo di EsoGuard nella triage dei pazienti a rischio e nell'abilitare un uso efficiente delle risorse endoscopiche per la rilevazione precoce e la prevenzione del cancro esofageo.
Lucid Diagnostics Inc. (Nasdaq: LUCD) anunció que su EsoGuard® Esophageal DNA Test para la detección temprana del precáncer esofágico será destacado en la Reunión Anual de la American Foregut Society (AFS) 2024 que se llevará a cabo del 26 al 28 de septiembre de 2024. El Dr. Dan Lister, presidente electo de la AFS, dirigirá una sesión titulada "Finding Barrett's - ¿Es hora de dejar de lado el endoscopio?" donde se discutirá EsoGuard como una alternativa no invasiva para el cribado mediante endoscopía superior.
Esto sigue a una reciente carta abierta de la AFS que aboga por la cobertura de políticas médicas para EsoGuard por parte de los aseguradores comerciales, enfatizando su sólida evidencia científica y su incorporación en las prácticas médicas de los doctores de la AFS. La sesión explorará el papel de EsoGuard en la clasificación de pacientes en riesgo y en la utilización eficiente de los recursos endoscópicos para la detección temprana y prevención del cáncer esofágico.
루시드 진단(Long Diagnostics Inc. (Nasdaq: LUCD)은 조기 식도 암 전암 검출을 위한 EsoGuard® 식도 DNA 검사가 2024년 9월 26일부터 28일까지 개최되는 미국 전위학회(American Foregut Society, AFS) 연례 회의에서 강조될 것이라고 발표했습니다. AFS 회장 선출인 Dan Lister 박사가 주도하는 세션 "Finding Barrett's - 내시경을 버릴 때인가?"에서 EsoGuard를 상부 내시경 검사에 대한 비침습적 대안으로 논의할 것입니다.
이번 발표는 상업 보험 제공자에 의해 EsoGuard의 의료 정책 보장을 옹호하는 AFS의 최근 공개 서한을 따르며, EsoGuard의 강력한 과학적 증거와 AFS 의사들의 실무에 통합된 점을 강조합니다. 이 세션은 위험에 처한 환자를 분류하고 식도암의 조기 발견 및 예방을 위해 내시경 자원을 효율적으로 사용하는 EsoGuard의 역할을 탐구할 것입니다.
Lucid Diagnostics Inc. (Nasdaq: LUCD) a annoncé que son EsoGuard® Test ADN œsophagien pour la détection précoce des précurseurs du cancer de l'œsophage sera mis en avant lors de la Réunion Annuelle de la American Foregut Society (AFS) 2024, qui se tiendra du 26 au 28 septembre 2024. Le Dr Dan Lister, président élu de l'AFS, animera une session intitulée "Finding Barrett's - Il est temps d'abandonner la sonde?" discutant d'EsoGuard comme une alternative non invasive à la dépistage par endoscopie supérieure.
Cela fait suite à une récente lettre ouverte de l'AFS plaidant pour une couverture médicale de l'EsoGuard par les payeurs commerciaux, soulignant ses solides preuves scientifiques et son intégration dans les pratiques des médecins de l'AFS. La session explorera le rôle d'EsoGuard dans le triage des patients à risque et l'utilisation efficace des ressources endoscopiques pour la détection précoce et la prévention du cancer de l'œsophage.
Lucid Diagnostics Inc. (Nasdaq: LUCD) gab bekannt, dass ihr EsoGuard® Esophagealer DNA-Test zur frühzeitigen Erkennung von Speiseröhren-Vorläufererkrankungen auf dem Jahrestreffen der American Foregut Society (AFS) 2024 vom 26. bis 28. September 2024 hervorgehoben wird. Dr. Dan Lister, designierter Präsident der AFS, wird eine Sitzung mit dem Titel "Finding Barrett's - Zeit, das Endoskop abzulehnen?" leiten, in der EsoGuard als nicht-invasive Alternative zur oberen Endoskopie vorgestellt wird.
Dies folgt auf einen kürzlich veröffentlichten offenen Brief der AFS, der sich für eine medizinische Richtlinienabdeckung von EsoGuard durch kommerzielle Versicherer einsetzt und die starke wissenschaftliche Evidenz sowie die Integration in die Praktiken der AFS-Ärzte hervorhebt. In der Sitzung wird die Rolle von EsoGuard bei der Triage von Risikopatienten und der effektiven Nutzung von Endoskopie-Ressourcen zur frühzeitigen Erkennung und Prävention von Speiseröhrenkrebs untersucht.
- EsoGuard test highlighted at prestigious American Foregut Society's 2024 Annual Meeting
- AFS strongly endorses EsoGuard for medical policy coverage by commercial payors
- EsoGuard recognized as an effective non-invasive alternative to screening upper endoscopy
- None.
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors
During the meeting, Dan Lister, M.D., current President-elect and one of the co-founders of the AFS, will lead a session titled "Finding Barrett's - Time to Ditch the Scope?" where he will discuss the value and utility of EsoGuard as a highly effective non-invasive alternative to screening upper endoscopy (EGD) for detecting esophageal precancer (Barrett's Esophagus or BE). This session follows the AFS's recent open letter, which highlights the critical need for early detection of esophageal precancer to prevent highly lethal esophageal cancer and strongly advocates for medical policy coverage of EsoGuard by commercial payors. The letter emphasizes the strong scientific evidence supporting the use of EsoGuard as a minimally invasive alternative to screening EGD and its incorporation in the practices of AFS physicians. Dr. Lister's session will explore how EsoGuard serves as a powerful tool to triage at-risk patients, thus enabling more efficient use of endoscopy resources while enabling effective early detection of esophageal precancer and facilitating surveillance and treatment to prevent progression to cancer.
"We are honored to once again participate in the AFS Annual Meeting, especially following their recent strong endorsement of EsoGuard," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We are grateful to the AFS and its leaders, including Dr. Lister, for their vocal advocacy in support of esophageal precancer testing to prevent esophageal cancer, and the critical role EsoGuard is playing as the first and only commercially available non-endoscopic biomarker test designed to do so. We have been proud to support the AFS since its inception and appreciate their efforts at the vanguard of esophageal health and cancer prevention."
The AFS Annual Meeting is a premier event that brings together gastroenterologists and surgeons to collaborate on personalizing treatment and improving patient outcomes for foregut diseases. The conference covers a wide range of topics, including diagnostics, novel therapies, and the latest advancements in foregut health.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/american-foregut-societys-2024-annual-meeting-to-highlight-lucid-diagnostics-esoguard-esophageal-precancer-test-302256688.html
SOURCE Lucid Diagnostics
FAQ
What is the EsoGuard Esophageal DNA Test being highlighted at the AFS 2024 Annual Meeting?
Why is the American Foregut Society (AFS) endorsing Lucid Diagnostics' EsoGuard test?
When and where is the American Foregut Society's 2024 Annual Meeting featuring Lucid Diagnostics' EsoGuard?
